Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. - Wikidata - wikimedia - TriplyDB

Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.

Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.

http://www.wikidata.org/entity/Q35054593

about

Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.

http://www.wikidata.org/entity/Q35054593

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Mycophenolate mofetil-based sa ...... f tacrolimus and/or sirolimus.

@ast

Mycophenolate mofetil-based sa ...... f tacrolimus and/or sirolimus.

@en

type

label

Mycophenolate mofetil-based sa ...... f tacrolimus and/or sirolimus.

@ast

Mycophenolate mofetil-based sa ...... f tacrolimus and/or sirolimus.

@en

prefLabel

Mycophenolate mofetil-based sa ...... f tacrolimus and/or sirolimus.

@ast

Mycophenolate mofetil-based sa ...... f tacrolimus and/or sirolimus.

@en

P1433

Q35054593-5C931B22-55E6-4E38-BFBB-B8FD71B3E49F

P1476

Q35054593-0439D28B-7201-4261-AB61-1E77964C53CF

P2093

Q35054593-07143BB6-B2A3-449C-940B-AFF0C7BCF348

Q35054593-27E435EB-A780-4A7A-B3DA-A69780AF95B8

Q35054593-31FD5622-3CF8-4707-A8CA-2248FE3001A2

Q35054593-50BBBCCA-5AA8-4E20-BF14-5D315661A0CD

Q35054593-631C0C20-7B7F-43FB-99B0-79B833801B64

Q35054593-72C38C40-C6A6-4D38-BAD0-7074FBBBC1AF

Q35054593-7986C0AC-00D9-4CA5-B1C3-E1C6DCF090F1

Q35054593-8C23C9AF-02A9-4A7A-ABDF-C8E22373BDEF

Q35054593-B7479F0C-5A66-41EF-995D-3F068B29206D

Q35054593-D8C5605C-C6D1-4596-A4A1-00A7A51A47A5

P2860

Q35054593-1A2D1412-FDFD-4C6F-BF61-D52CD2D19C28

Q35054593-27CDB35F-D367-476A-820D-E4BDD829A059

Q35054593-2DAB5FC5-F571-4103-B4F4-6175A8B5F3B3

Q35054593-56C1CFC2-ED8E-4C68-8D6F-7AF8F2EAD224

Q35054593-74544C3E-7A29-4F8D-9173-032E60FE0BEC

Q35054593-8EBCE05F-7442-4E13-9782-1E70668AB7CE

Q35054593-90D064CE-47F5-4F80-81D4-29D612EA3B1A

Q35054593-D9625E16-5610-4A6D-9AED-DB0F575454AB

Q35054593-FF77DBB4-3A58-4B90-955F-F8B3E06AF6F9

P2888

Q35054593-F1046238-AD8A-4859-A751-694DAF665A68

P304

Q35054593-E7B70360-90D7-4608-816D-CCB221FE1A91

P31

Q35054593-40522DFE-E33F-4F9E-83CA-1683206C7145

P356

Q35054593-B4ED990E-81D1-4806-9646-B208B59D8A8E

P407

Q35054593-8FCD37A0-6839-4A6A-92E8-C394761CA89D

P433

Q35054593-7C209F01-74B5-4AED-ABB7-42855B70EE46

P478

Q35054593-0C609BF4-B273-4033-96F5-C51B16A3D0F3

P577

Q35054593-724E9C01-83E9-4FEF-B806-CF6DCF9E6982

P698

Q35054593-693F978A-A5FF-4BFC-BEE9-5C08C3374EB5

P932

Q35054593-C97B472B-1E4F-4353-A72F-3549C0F20C21

P356

P1433

Bone Marrow Transplantation

P1476

Mycophenolate mofetil-based sa ...... f tacrolimus and/or sirolimus.

@en

P2093

H Ali

http://www.w3.org/2001/XMLSchema#string

J Palmer

http://www.w3.org/2001/XMLSchema#string

P Parker

http://www.w3.org/2001/XMLSchema#string

R Nakamura

http://www.w3.org/2001/XMLSchema#string

S H Thomas

http://www.w3.org/2001/XMLSchema#string

S J Forman

http://www.w3.org/2001/XMLSchema#string

S Khaled

http://www.w3.org/2001/XMLSchema#string

S Shayani

http://www.w3.org/2001/XMLSchema#string

T Stiller

http://www.w3.org/2001/XMLSchema#string

Z Eroglu

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.

P2888

P304

307-309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2014.245

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25365064

http://www.w3.org/2001/XMLSchema#string

P932

4318766

http://www.w3.org/2001/XMLSchema#string